Hall Jesse Wayne 4

What Happened
Jesse Wayne Hall, Chief Medical Officer of Aclaris Therapeutics (ACRS), received two restricted stock unit (RSU) awards on February 2, 2026 totaling 441,400 RSUs (98,100 + 343,300). Each RSU represents a contingent right to one share; the awards were granted at $0.00 (no cash paid) and are recorded as derivative acquisitions in the Form 4.

Key Details

• Transaction date: February 2, 2026; Form 4 filed February 6, 2026.
• Grant details: 98,100 RSUs and 343,300 RSUs, grant price $0.00; total RSUs = 441,400.
• Value: No cash was paid at grant; economic value depends on future stock price when RSUs settle.
• Vesting: The shares underlying these RSUs vest in four equal installments on the 1st, 2nd, 3rd and 4th anniversaries of February 2, 2026, subject to continuous service (see footnote F2).
• Footnotes: F1 — each RSU converts to one common share upon settlement; F3 describes a 25%/four-year vesting arrangement for options (no option exercise reported in this filing).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Filed Feb 6, 2026, four days after the grant (Form 4s are normally due within 2 business days), so this filing appears later than the typical 2-business-day deadline.

Context
RSU grants are a form of compensation and do not represent an open-market purchase (so they’re not a direct bullish purchase signal). They convert to actual shares only as they vest and subject to continued employment; tax withholding or other mechanics may apply at settlement. This filing reports the award/grant (derivative grant) rather than a sale, purchase, or option exercise.